1. Home
  2. CGTL vs SAVA Comparison

CGTL vs SAVA Comparison

Compare CGTL & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGTL
  • SAVA
  • Stock Information
  • Founded
  • CGTL 2016
  • SAVA 1998
  • Country
  • CGTL Hong Kong
  • SAVA United States
  • Employees
  • CGTL N/A
  • SAVA N/A
  • Industry
  • CGTL
  • SAVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CGTL
  • SAVA Health Care
  • Exchange
  • CGTL NYSE
  • SAVA Nasdaq
  • Market Cap
  • CGTL 70.3M
  • SAVA 137.2M
  • IPO Year
  • CGTL 2024
  • SAVA N/A
  • Fundamental
  • Price
  • CGTL $4.41
  • SAVA $1.38
  • Analyst Decision
  • CGTL
  • SAVA Buy
  • Analyst Count
  • CGTL 0
  • SAVA 3
  • Target Price
  • CGTL N/A
  • SAVA $54.50
  • AVG Volume (30 Days)
  • CGTL 96.6K
  • SAVA 2.2M
  • Earning Date
  • CGTL 05-15-2025
  • SAVA 05-09-2025
  • Dividend Yield
  • CGTL N/A
  • SAVA N/A
  • EPS Growth
  • CGTL 35.72
  • SAVA N/A
  • EPS
  • CGTL 0.21
  • SAVA N/A
  • Revenue
  • CGTL $35,611,761.00
  • SAVA N/A
  • Revenue This Year
  • CGTL N/A
  • SAVA N/A
  • Revenue Next Year
  • CGTL N/A
  • SAVA N/A
  • P/E Ratio
  • CGTL $20.08
  • SAVA N/A
  • Revenue Growth
  • CGTL N/A
  • SAVA N/A
  • 52 Week Low
  • CGTL $2.80
  • SAVA $1.35
  • 52 Week High
  • CGTL $10.59
  • SAVA $42.20
  • Technical
  • Relative Strength Index (RSI)
  • CGTL N/A
  • SAVA 23.37
  • Support Level
  • CGTL N/A
  • SAVA $1.63
  • Resistance Level
  • CGTL N/A
  • SAVA $1.79
  • Average True Range (ATR)
  • CGTL 0.00
  • SAVA 0.19
  • MACD
  • CGTL 0.00
  • SAVA -0.14
  • Stochastic Oscillator
  • CGTL 0.00
  • SAVA 1.76

About CGTL CREATIVE GLOBAL TECHNOLOGY HOLDINGS LIMITED

Creative Global Technology Holdings Ltd conducts its business through its subsidiary, which is a Hong Kong-based company sourcing and reselling recycled consumer electronic devices, currently mostly smartphones, tablets, and laptops.

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Share on Social Networks: